Evidence for prostate cancer-associated diagnostic marker-1: immunohistochemistry and in situ hybridization studies

Clin Cancer Res. 2004 Apr 1;10(7):2452-8. doi: 10.1158/1078-0432.ccr-03-0170.


Purpose: The purpose of this study was to characterize a novel gene/protein associated with prostate cancer, termed prostate cancer-associated diagnostic marker-1 [PCADM-1 (Hu Y, Wang M, Garcia FU, Aoyaki K, Stearns ME. Identification of PCADM-1 as a novel diagnostic marker for prostate cancer, submitted for publication)].

Experimental design and results: Immunological studies revealed that rabbit polyclonal antibodies generated against recombinant PCADM-1 specifically recognize the protein in crude protein extracts from a variety of prostate cancer cell lines (i.e., PC-3 ML, LNCaP, DU145, and CPTX-1532) and prostate cancer tissue. Combined immunolabeling and in situ hybridization studies demonstrated that PCADM-1 mRNA was expressed by the luminal epithelial cells of prostate cancer glands and was not expressed by high-grade prostatic intraepithelial neoplasia or HPV-MLC7 cells. Immunolabeling studies of tissue arrays from biopsies of archival material (n = 200 samples) confirmed that PCADM-1 was expressed by the luminal epithelial cells of prostate cancer.

Conclusions: Taken together, the data suggest that PCADM-1 is a specific marker for human prostate cancer.

MeSH terms

  • Antigens, Neoplasm / biosynthesis*
  • Antigens, Neoplasm / genetics*
  • Biomarkers, Tumor*
  • Blotting, Western
  • Cell Line
  • Cell Line, Tumor
  • Humans
  • Hyperplasia
  • Immunohistochemistry
  • In Situ Hybridization
  • Male
  • Prostate / metabolism
  • Prostatic Intraepithelial Neoplasia / pathology
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology
  • RNA, Messenger / metabolism
  • Recombinant Proteins / chemistry
  • Software


  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • RNA, Messenger
  • Recombinant Proteins